Filtered By:
Specialty: Cardiology
Condition: Bleeding
Drug: Clopidogrel

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 388 results found since Jan 2013.

Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis
Conclusions The effect of more potent P2Y12 inhibitors compared with clopidogrel on efficacy and safety end points is consistent in elderly and younger patients. These data imply that potent P2Y12 inhibitors should not be withheld from eligible patients solely because of advanced age.
Source: American Heart Journal - November 9, 2017 Category: Cardiology Source Type: research

Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications
AbstractPurpose of ReviewPlatelets are activated upon interaction with injured vascular endothelium to form a primary hemostatic plug. Pathogenic thrombosis driven by platelet aggregation can occur in the setting of vascular disease leading to ischemic events. The use of antiplatelet agents has become a mainstay for prevention of the secondary complications of vascular disease. This review summarizes seminal and recent literature related to this area.Recent FindingsAspirin is a cornerstone of antiplatelet therapy for coronary artery disease and cerebrovascular disease for prevention of myocardial infarction, stroke, and va...
Source: Current Atherosclerosis Reports - November 4, 2017 Category: Cardiology Source Type: research

Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan.
CONCLUSIONS: In real-world AMI Taiwanese patients, ticagrelor seemed to offer better anti-ischemic protection than clopidogrel, without an increase in the rate of major bleeding. A large-scale randomized trial is needed to assess the efficacy and safety of ticagrelor in East Asian AMI patients. PMID: 29081474 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 27, 2017 Category: Cardiology Authors: Lee CH, Cheng CL, Kao Yang YH, Chao TH, Chen JY, Li YH Tags: Circ J Source Type: research

Evaluation of the Safety and Efficacy of an Edoxaban-based Antithrombotic Regimen in Patients with Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) with Stent Placement: Rationale and Design of the ENTRUST-AF PCI Trial
Publication date: Available online 23 October 2017 Source:American Heart Journal Author(s): Pascal Vranckx, Thorsten Lewalter, Marco Valgimigli, Jan G. Tijssen, Paul-Egbert Reimitz, Lars Eckardt, Hans-Joachim Lanz, Wolfgang Zierhut, Rüdiger Smolnik, Andreas Goette Background The optimal antithrombotic treatment after percutaneous coronary intervention (PCI) with stenting in patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was non-inferior to a vitamin-K antagonist (VKA) with respect to the prevention of stroke or systemic embolism and was associated with significantly lower rate...
Source: American Heart Journal - October 23, 2017 Category: Cardiology Source Type: research

Focused update on dual antiplatelet treatment : ESC guidelines 2017.
This article summarizes and assesses the major recommendations given in the Focused Update DAPT 2017 of the European Society of Cardiology (ESC). In particular the recommendations address strategies to reduce an increased risk of bleeding based on clinical predictors. PMID: 29043405 [PubMed - as supplied by publisher]
Source: Herz - October 19, 2017 Category: Cardiology Tags: Herz Source Type: research

The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment Data.
CONCLUSION: The use of new antiplatelet agents is rapidly increasing, and they have been used more commonly than clopidogrel since 2015. We demonstrated that new antiplatelet agents have a favorable effect on reducing 30-day mortality in AMI patients in Korea. PMID: 29035430 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - October 18, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study
Conclusions Although risks for 1-year MACE were significantly higher in ACS PCI patients with versus without CKD, prasugrel use was 50% lower in patients with renal impairment. Irrespective of CKD status, outcomes associated with prasugrel use were not significant after propensity adjustment. These data highlight the need for randomized studies evaluating the optimal antiplatelet therapy in CKD patients with ACS.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 16, 2017 Category: Cardiology Authors: Baber, U., Chandrasekhar, J., Sartori, S., Aquino, M., Kini, A. S., Kapadia, S., Weintraub, W., Muhlestein, J. B., Vogel, B., Faggioni, M., Farhan, S., Weiss, S., Strauss, C., Toma, C., DeFranco, A., Baker, B. A., Keller, S., Effron, M. B., Henry, T. D., Tags: Coronary Source Type: research

Efficacy and Safety of Potent Platelet P2Y12 Receptor Inhibitors in Elderly vs. Non-elderly Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Conclusions The effect of more potent P2Y12 inhibitors compared to clopidogrel on efficacy and safety endpoints is consistent in elderly and younger patients. These data imply that potent P2Y12 inhibitors should not be withheld from eligible patients solely because of advanced age.
Source: American Heart Journal - September 22, 2017 Category: Cardiology Source Type: research

A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study
Conclusion: HOPE-TAILOR is a prospective, randomized, open-label, blinded, endpoint study to explore the efficacy and safety of novel P2Y12 receptor inhibitors administered orally at half the dose in Korean patients with ACS. The results will be available late in 2017.Cardiology 2017;138:201-206
Source: Cardiology - August 15, 2017 Category: Cardiology Source Type: research

Gender ‐related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry
ConclusionsIn a contemporary “real‐life” cohort of patients with ACS treated with PCI and focusing on antiplatelet treatment 1‐year ischemic outcome does not differ by gender, while women do present more frequently not actionable bleeding events.
Source: Cardiovascular Therapeutics - July 14, 2017 Category: Cardiology Authors: Ioanna Xanthopoulou, Periklis Davlouros, Spyridon Deftereos, Michalis Hamilos, George Sitafidis, Ioannis Kanakakis, Manolis Vavouranakis, John Goudevenos, John Lekakis, Dimitrios Alexopoulos Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial
Conclusions This small trial showed that SAPT (vs. DAPT) tended to reduce the occurrence of major adverse events following TAVR. SAPT reduced the risk for major or life-threatening events while not increasing the risk for MI or stroke. Larger studies are needed to confirm these results. (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation: The ARTE Trial [ARTE], NCT01559298; Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI [ARTE], NCT02640794)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - July 3, 2017 Category: Cardiology Authors: Rodes-Cabau, J., Masson, J.-B., Welsh, R. C., Garcia del Blanco, B., Pelletier, M., Webb, J. G., Al-Qoofi, F., Genereux, P., Maluenda, G., Thoenes, M., Paradis, J.-M., Chamandi, C., Serra, V., Dumont, E., Cote, M. Tags: Structural Source Type: research

6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel)
Conclusions Two-year outcomes in the ITALIC trial confirmed the 1-year results and showed that patients receiving 6-month DAPT after percutaneous coronary intervention with second-generation drug-eluting stent have similar outcomes to those receiving 24-month DAPT.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - June 19, 2017 Category: Cardiology Authors: Didier, R., Morice, M. C., Barragan, P., Noryani, A. A. L., Noor, H. A., Majwal, T., Hovasse, T., Castellant, P., Schneeberger, M., Maillard, L., Bressolette, E., Wojcik, J., Delarche, N., Blanchard, D., Jouve, B., Ormezzano, O., Paganelli, F., Levy, G., Tags: Coronary Source Type: research

Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non –ST‐segment elevation acute coronary syndrome in the PLATO trial
ConclusionsThe benefit of ticagrelor over clopidogrel was consistent in those undergoing early and late angiography, supporting upstream use of ticagrelor.
Source: Clinical Cardiology - June 9, 2017 Category: Cardiology Authors: Charles V. Pollack, Farideh Davoudi, Deborah B. Diercks, Richard C. Becker, Stefan K. James, Soo Teik Lim, Phillip J. Schulte, Jindrich Spinar, Philippe Gabriel Steg, Robert F. Storey, Anders Himmelmann, Lars Wallentin, Christopher P. Cannon, Tags: CLINICAL INVESTIGATIONS Source Type: research

Antiplatelet treatments: recent evidence from randomized controlled trials
Purpose of review: To provide an overview of selected randomized studies reported over the last 2 years evaluating antiplatelet therapies in patients with either acute or stable manifestations of atherosclerosis. Recent findings: From large outcome trials included evidence for reduced risk of ischemic events associated with use of ticagrelor and aspirin versus aspirin alone, albeit with an increased bleeding risk in patients with stable coronary artery disease and history of myocardial infarction. No benefit regarding ischemic outcomes could be demonstrated for ticagrelor monotherapy compared with aspirin or clopidogrel i...
Source: Current Opinion in Cardiology - June 7, 2017 Category: Cardiology Tags: CLINICAL TRIALS: Edited by Neal S. Kleiman Source Type: research

Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents
Conclusions Among patients receiving DES implantation, AF was not rare and was associated with increased ischemic and bleeding risk. In patients with AF, triple therapy was not associated with decreased ischemic events but was associated with increased bleeding risk compared to DAPT.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - June 5, 2017 Category: Cardiology Authors: Choi, H.-I., Ahn, J.-M., Kang, S. H., Lee, P. H., Kang, S.-J., Lee, S.-W., Kim, Y.-H., Lee, C. W., Park, S.-W., Park, D.-W., Park, S.-J. Tags: Coronary Source Type: research